Showing results (81-90 of 142) with videos related to

Sort By:
Pageof 15
Journal of the Advanced Practitioner in Oncology|October 9, 2023
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple MyelomaRakesh Popat, Sagar Lonial, Peter M Voorhees, et al.
Clinical Pharmacology and Therapeutics|November 19, 2016
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple MyelomaX S Xu, X Yan, T Puchalski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple MyelomaSikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, et al.
Blood|June 27, 2007
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaDeborah J Kuhn, Qing Chen, Peter M Voorhees, et al.
British Journal of Haematology|January 19, 2011
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myelomaSally A Hunsucker, Valeria Magarotto, Deborah J Kuhn, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 InstitutesCindy Varga, Myra Robinson, Vikas Gupta, et al.
Cancer Treatment and Research Communications|March 19, 2026
Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemiaMounzer E Agha, Sarah McGregor, Kevin C De Braganca, et al.
Circulation Research|March 20, 2026
Phosphoinositide Depletion and Compensatory Phospho-Signaling in Angiotensin II-Induced Heart Disease: Protection Through PTEN InhibitionMaartje Westhoff, Taylor L Voelker, Silvia G Del Villar, et al.
European Journal of Haematology|June 13, 2023
Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myelomaShebli Atrash, Myra Robinson, Alankrita Taneja, et al.
Ejhaem|July 18, 2022
Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myelomaDavid M Foureau, Manisha Bhutani, Myra Robinson, et al.
Pageof 15